Insulet Celebrates New Global Headquarters and U.S. Manufacturing Facility in Acton, MA
ACTON, Mass.--(BUSINESS WIRE)--May 2, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, will host a ribbon cutting ceremony today to celebrate the official grand opening of the Company’s new global headquarters and U.S. manufacturing facility in Acton, Massachusetts.
The new facility, located on a 26-acre site, which represents an over $200 million investment in Massachusetts, has already created hundreds of local jobs, and provides additional manufacturing capabilities closer to Insulet’s large and growing U.S. customer base. The new U.S. manufacturing operation is also expected to drive operating efficiencies and increase productivity. The Company recently began production.
Massachusetts Governor, Charlie Baker, will join Insulet speakers Shacey Petrovic, President and Chief Executive Officer, and Chuck Alpuche, Executive Vice President and Chief Operating Officer, to commemorate the ribbon cutting ceremony. Other special guests include: Massachusetts State Senator Jamie Eldridge; Travis McCready, President and Chief Executive Officer of the Massachusetts Life Sciences Center; dignitaries from the Commonwealth of Massachusetts; and members of Insulet’s loyal Podder community.
“As a global hub for innovation and research, Massachusetts is well-positioned to expand its advanced manufacturing footprint,” said Governor Charlie Baker. “Our Administration has prioritized efforts to create an environment that supports the growth of companies like Insulet, and we are glad to see them open this new facility and create jobs here in the Commonwealth.”
“We are honored to call Massachusetts our home and are truly grateful for the strong partnership with the Commonwealth of Massachusetts and town of Acton. They have been tremendous supporters of this monumental milestone for Insulet,” said Shacey Petrovic, President and Chief Executive Officer. “Our new global headquarters and U.S. manufacturing facility is a launchpad for continued growth and exciting innovation and we’re proud to be contributing to the economy by creating hundreds of local jobs.”
For more about Insulet’s future innovation pipeline, please visit myomnipod.com/innovation.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission in February 2019 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
© 2019 Insulet Corporation. Omnipod, and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All other trademarks are the property of their respective owners. All rights reserved.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005041/en/
CONTACT: Investor and Corporate Communications Contact:
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
Natalie Toomey, 978-600-7421
Marketing Manager, Global Public Relations & Field Programs
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES DIABETES
SOURCE: Insulet Corporation
Copyright Business Wire 2019.
PUB: 05/02/2019 06:00 AM/DISC: 05/02/2019 06:00 AM